The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions

MedComm, Journal Year: 2025, Volume and Issue: 6(3)

Published: March 1, 2025

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, predominantly associated with chronic hepatitis B virus (HBV) and C (HCV) infections. These infections drive persistent liver inflammation, culminating in cellular dysregulation, fibrosis, cancer. Despite advancements targeted therapies, drug resistance the lack reliable biomarkers for patient stratification still terribly hinder treatment viral HCC. To this end, review delves into intricate mechanisms underlying malignant transformation to HCC, including integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, immune escape, abnormal signaling pathways, highlighting their complex interactions synergies. Cutting-edge preclinical clinical HCC management, lifestyle immunotherapies, gene-based approaches, innovative treatments, are further investigated, particular priority given therapeutic potential future applications overcoming current limitations. By synthesizing recent scientific insights, aims deepen understanding pathogenesis context hepatitis, paving way novel targets personalized strategies, ultimately improving outcomes.

Language: Английский

---

Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Sept. 3, 2024

Language: Английский

---

Recent advances of injectable in situ-forming hydrogels for preventing postoperative tumor recurrence

Drug Delivery, Journal Year: 2024, Volume and Issue: 31(1)

Published: Sept. 10, 2024

The unavoidable residual tumor tissue from surgery and the strong aggressiveness of cells pose challenges to postoperative treatment patients, accompanied by in situ recurrence decreased quality life. Therefore, there is an urgent need explore appropriate therapeutic strategies remove after inhibit metastasis surgery. In recent years, with rapid development biomedical materials, study local delivery systems as agents has gradually attracted attention researchers. Injectable situ-forming hydrogel a locally administered agent injected solution that can be loaded various rapidly gels form semi-solid gel at site. This type tightly fills surgical site covers irregular excision surfaces. this paper, we review advances application injectable hydrogels therapy, focusing on matrix materials its different types tumors, well discussing prospects clinical application.

Language: Английский

---

Innovative applications and research progress of hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma

World Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 17(2)

Published: Jan. 18, 2025

This article provides an in-depth analysis of the study conducted by Wang et al, which explores hepatic arterial infusion chemotherapy and its synergistic strategies in managing advanced hepatocellular carcinoma (HCC). HCC ranks as fourth most common cause cancer-related mortality globally is frequently associated with portal vein tumor thrombus (PVTT). The approach to HCC, particularly when PVTT present, diverges markedly between Eastern Western practices. These differences are rooted variations epidemiology, etiology, pathology, comorbidities, prognosis. paper delves into diagnosis, classification, treatment for PVTT, well evolving role advancements therapeutic landscape HCC.

Language: Английский

---

Sorafenib—Drug Delivery Strategies in Primary Liver Cancer

Journal of Functional Biomaterials, Journal Year: 2025, Volume and Issue: 16(4), P. 148 - 148

Published: April 21, 2025

Current primary liver cancer therapies, including sorafenib and transarterial chemoembolization, face significant limitations due to chemoresistance caused by impaired drug uptake, altered metabolism, other genetic modulations. These challenges contribute relapse rates of 50–80% within five years. The need for improved treatment strategies (adjuvant therapy, unsatisfactory enhanced permeability retention (EPR) effect) has driven research into advanced delivery systems, targeted nanoparticles, biomaterials, combinatory approaches. Therefore, this review evaluates recent advancements in pharmacotherapy, focusing on the potential systems its derivatives. Approaches such as leveraging Kupffer cells tumor migration or utilizing smaller NPs inter-/intracellular delivery, address EPR limitations. Biomaterials therapies targeting have demonstrated effectiveness increasing tumor-specific but clinical evidence remains limited. Combination emerged an interesting solution overcoming broadening therapeutic functionality. Biomimetic employing blood exosomes, provide methods tumors, preventing metastasis, strengthening immune responses. However, differences between preclinical models human physiology remain a barrier translating these findings success. Future must focus development adjuvant therapy refining overcome heterogeneity low accumulation.

Language: Английский

---

Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer

Materials Today Bio, Journal Year: 2024, Volume and Issue: 29, P. 101358 - 101358

Published: Nov. 23, 2024

Language: Английский

---